Kimia Farma Tbk PT
IDX:KAEF

Watchlist Manager
Kimia Farma Tbk PT Logo
Kimia Farma Tbk PT
IDX:KAEF
Watchlist
Price: 600 IDR Market Closed
Market Cap: 3.3T IDR
Have any thoughts about
Kimia Farma Tbk PT?
Write Note

Kimia Farma Tbk PT
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Kimia Farma Tbk PT
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Kimia Farma Tbk PT
IDX:KAEF
Total Liabilities & Equity
Rp16.8T
CAGR 3-Years
-4%
CAGR 5-Years
-1%
CAGR 10-Years
20%
T
Tempo Scan Pacific Tbk PT
IDX:TSPC
Total Liabilities & Equity
Rp12.2T
CAGR 3-Years
8%
CAGR 5-Years
9%
CAGR 10-Years
8%
Kalbe Farma Tbk PT
IDX:KLBF
Total Liabilities & Equity
Rp28.8T
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
9%
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
Total Liabilities & Equity
Rp2.3T
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
6%
Soho Global Health Tbk PT
IDX:SOHO
Total Liabilities & Equity
Rp4.7T
CAGR 3-Years
4%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Pyridam Farma Tbk PT
IDX:PYFA
Total Liabilities & Equity
Rp5.9T
CAGR 3-Years
111%
CAGR 5-Years
99%
CAGR 10-Years
43%
No Stocks Found

Kimia Farma Tbk PT
Glance View

Market Cap
3.3T IDR
Industry
Pharmaceuticals

PT Kimia Farma Tbk engages in the production and distribution of healthcare products. The company is headquartered in Jakarta, Dki Jakarta and currently employs 11,668 full-time employees. The company went IPO on 2001-07-04. The firm produces medical devices and chemical materials. The firm is also involved in producing vegetable oil, iodine, and salts. Its products include Glucokaf, Diazink, Oracef, Kifarox, Magacid Suspension, Magaside Chewable Tablets, Nitrocafe Retarded, Nitrocafe Retard Forte, Trinolon, Raistine, VAGIZOL, Neviral, Hiviral Tablet, Duviral, Codipront Cum Expectorant, RETHAPHYL SR, and SUPRAFLU. Its generic products include PETHIDIN Hcl, PARACETAMOL, Diclofenac Sodium, MEPHANAMIC ACID, ANTALGIN, ANTASIDE DOEN, PYRANTEL, ALBENDAZOLE, METRONIDAZOLE TABLET, NEO BLOOD ADDING TABLET, FERROUS SULOATE SYRUP, DIMENHYDRINATE, ACYCLOVIR, AMBROXOL HCL, CHLOROQUINE, CHLORPROMAZINE HCL, CODEIN, CLOPIDOGREL, ERGOTAMINE COFFEE, METHYLERGOMETRINE TABLET SALUTE, MELOXICAM, and Pherphenazine.

KAEF Intrinsic Value
1 038.26 IDR
Undervaluation 42%
Intrinsic Value
Price

See Also

What is Kimia Farma Tbk PT's Total Liabilities & Equity?
Total Liabilities & Equity
16.8T IDR

Based on the financial report for Sep 30, 2024, Kimia Farma Tbk PT's Total Liabilities & Equity amounts to 16.8T IDR.

What is Kimia Farma Tbk PT's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
20%

Over the last year, the Total Liabilities & Equity growth was -18%. The average annual Total Liabilities & Equity growth rates for Kimia Farma Tbk PT have been -4% over the past three years , -1% over the past five years , and 20% over the past ten years .

Back to Top